title: Immunosenescence and hurdles in the clinical management of older HIV-patients.
abstract: People living with HIV (PLWH) who are treated with effective highly active antiretroviral therapy (HAART) have a similar life expectancy to the general population. Moreover, an increasing proportion of new HIV diagnoses are made in people older than 50 y. The number of older HIV-infected patients is thus constantly growing and it is expected that by 2030 around 70% of PLWH will be more than 50 y old. On the other hand, HIV infection itself is responsible for accelerated immunosenescence, a progressive decline of immune system function in both the adaptive and the innate arm, which impairs the ability of an individual to respond to infections and to give rise to long-term immunity; furthermore, older patients tend to have a worse immunological response to HAART. In this review we focus on the pathogenesis of HIV-induced immunosenescence and on the clinical management of older HIV-infected patients.
authors.affiliation: a Department of Infectious and Tropical Diseases , Ospedale San Raffaele , Milan , Italy.
authors.forename: Marco
authors.initials: M
authors.lastname: Ripa
authors.affiliation: a Department of Infectious and Tropical Diseases , Ospedale San Raffaele , Milan , Italy.
authors.forename: Stefania
authors.initials: S
authors.lastname: Chiappetta
authors.affiliation: a Department of Infectious and Tropical Diseases , Ospedale San Raffaele , Milan , Italy.
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Tambussi
mesh_terms: D000375:Aging; D023241:Antiretroviral Therapy, Highly Active; D015897:Comorbidity; D004347:Drug Interactions; D015658:HIV Infections / Q000188:drug therapy / Q000276:immunology* / Q000503:physiopathology* / Q000821:virology; D006801:Humans; D000068884:Immunosenescence
keywords: AIDS; HIV; comorbidities; drug-drug interactions; immunosenescence